<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662194</url>
  </required_header>
  <id_info>
    <org_study_id>ALF-55/08</org_study_id>
    <nct_id>NCT00662194</nct_id>
  </id_info>
  <brief_title>Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)</brief_title>
  <official_title>A Study of Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C or Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from this study will provide the first information how the innate immune system may be
      altered in HIV-HCV and HIV-HBV co-infected individuals, and describe Toll-like receptor
      changes with HIV co-infection therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been demonstrated that Toll-like receptors (TLR) are involved in viral hepatitis -
      hepatitis B (HBV), hepatitis C (HCV) - and HIV in the setting of mono-infection. However the
      role of innate immunity in the pathogenesis of HIV-hepatitis co-infection in both natural and
      therapy-associated viral clearance remains unclear. The data from this study may reveal
      patterns which could predict how and when patients spontaneously, and with therapy, resolve
      HBV or HCV in the setting of co-infection.

      The aim of the study is to evaluate the activity of innate immunity in different subsets of
      HIV-infected populations co-infected with chronic hepatitis B and/or C. Our hypothesis is
      that innate immunity is altered in HIV and hepatitis co-infection and that this differs from
      both hepatitis and HIV mono-infection.

      The study is a cross-sectional and longitudinal pilot study of individuals infected with HIV
      and either HBV or HCV.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TLR change with HIV co-infection therapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLR change patterns on spontaneously and on treatment resolved HBV or HCV in the co-infected setting</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV-hepatitis Co-infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count &gt; 500cells/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>HIV-HBV co-infected and receiving ART and CD4 count &lt;200cells/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>HIV-HBV co-infected and not receiving ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>HIV-HCV co-infected &amp; receiving anti-retroviral therapy (ART) and CD4 count &gt; 500cells/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <description>HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <description>HIV-HCV co-infected and receiving ART and CD4 count &lt;200cells/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <description>HIV-HCV co-infected and not receiving ART</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV and either HBV or HCV co-infection

          -  18 years and older

          -  able to give informed consent

        Exclusion Criteria:

          -  HIV-HBV-HCV triple infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Sasadeusz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Audsley, PhD</last_name>
    <phone>+613 99030184</phone>
    <email>jennifer.audsley@med.monash.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Audsley, PhD</last_name>
      <phone>+613 99030184</phone>
      <email>jennifer.audsley@med.monash.edu.au</email>
    </contact>
    <investigator>
      <last_name>David Iser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joe Sasadeusz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HBV</keyword>
  <keyword>HCV</keyword>
  <keyword>co-infection</keyword>
  <keyword>innate immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

